Japan – LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

0
2

LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

TOKYO and CAMBRIDGE, Mass., Oct. 14, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) revealed today that LEQEMBI ® IQLIK ™, a subcutaneous autoinjector formula of lecanemab (generic name), for the treatment of Alzheimer’s illness (ADVERTISEMENT)has actually been chosen by TIME as one of the “Best Inventions of 2025” in the Medical and Healthcare classification.

TIME’s yearly list of the very best Inventions functions 300 remarkable developments altering lives. To put together the 2025 list, TIME got elections from TIME editors and reporters around the globe, and through an online application procedure, paying unique attention to growing fields such as healthcare and AI. TIME then examined each competitor on a variety of essential elements, consisting of creativity, effectiveness, aspiration, and effect. For additional information, please see: https://time.com/collections/best-inventions-2025/.

LEQEMBI IQLIK is the very first and just anti-amyloid treatment to provide an at-home injection to assist clients and their care partners continue to slow illness development following the 18-month preliminary treatment duration. The treatment was authorized in the U.S. in August 2025 and introduced on October 6. LEQEMBI IQLIK uses clients and their care partners, the possible to reduce administration time (approximate injection time of 15 seconds), offering an alternative to continue treatment without having to stress about checking out an infusion. It has the prospective to decrease health care resources associated with intravenous (IV) upkeep dosing, such as preparation for infusion and nurse tracking, while increasing infusion capability for brand-new qualified clients to start initiation treatment and simplifying the total Advertisement treatment path.

LEQEMBI, acknowledged as one of TIME’s “Best Inventions of 2023,” is the very first authorized anti-amyloid treatment for advertisement revealed to slow illness development and cognitive and practical decrease in grownups with Mild Cognitive Impairment (MCI) or moderate dementia phase of illness (jointly described as early advertisement). LEQEMBI has actually been authorized in 50 nations and is under regulative evaluation in 10 nations. In early September, Eisai started a rolling Supplemental Biologics License Application (sBLA) to the U.S. FDA for LEQEMBI IQLIK as a subcutaneous beginning dosage for the treatment of early advertisement under Fast Track Status.

Eisai works as the lead of LEQEMBI advancement and regulative submissions internationally with Eisai and Biogen co-commercializing and co-promoting the item and Eisai having last decision-making authority.

For more information, please go to: https://www.eisai.com/news/2025/pdf/enews202572pdf.pdf

Copyright © 2025 JCN Newswire. All rights scheduled. A department of Japan Corporate News Network.